See more : Towne Bancorp, Inc. (TWNE) Income Statement Analysis – Financial Results
Complete financial analysis of Integrated BioPharma, Inc. (INBP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Integrated BioPharma, Inc., a leading company in the Packaged Foods industry within the Consumer Defensive sector.
- OTP Bank Nyrt. (OTP.BD) Income Statement Analysis – Financial Results
- Americanas S.A. (AMER3.SA) Income Statement Analysis – Financial Results
- Astellas Pharma Inc. (ALPMY) Income Statement Analysis – Financial Results
- Banco Comercial Português, S.A. (BPCGF) Income Statement Analysis – Financial Results
- Shandong Huifa Foodstuff Co.,Ltd. (603536.SS) Income Statement Analysis – Financial Results
Integrated BioPharma, Inc. (INBP)
About Integrated BioPharma, Inc.
Integrated BioPharma, Inc., together with its subsidiaries, manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products primarily in the United States, Luxembourg, and Canada. It operates through Contract Manufacturing and Other Nutraceutical Businesses segments. The Contract Manufacturing segment manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized healthcare providers. The Other Nutraceutical Businesses segment distributes healthful nutritional products for sale through mass market, grocery, drug, and vitamin retailers under the Peaceful Sleep and Wheatgrass brands, as well as other branded proprietary nutraceutical products. This segment also sells private label vitamin and nutritional supplement products through the Internet; provides warehousing and fulfilment services; and distributes fine natural botanicals, including multi minerals, as well as raw materials. The company was formerly known as Integrated Health Technologies, Inc. Integrated BioPharma, Inc. was incorporated in 1980 and is based in Hillside, New Jersey.
Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 50.32M | 50.67M | 56.25M | 63.56M | 52.77M | 49.98M | 43.71M | 46.95M | 42.21M | 37.49M | 33.68M | 33.62M | 36.60M | 25.13M | 37.02M | 39.37M | 49.94M | 60.16M | 57.82M | 32.74M | 25.28M | 22.24M | 23.55M | 15.29M | 17.97M | 12.30M | 16.00M | 11.10M | 10.60M |
Cost of Revenue | 46.43M | 46.61M | 49.69M | 54.08M | 46.04M | 43.76M | 38.72M | 40.29M | 36.71M | 33.10M | 28.80M | 28.12M | 29.00M | 21.36M | 29.21M | 29.59M | 41.43M | 42.74M | 35.98M | 30.74M | 19.39M | 17.11M | 18.84M | 13.82M | 16.31M | 11.30M | 12.40M | 9.20M | 8.00M |
Gross Profit | 3.88M | 4.06M | 6.55M | 9.48M | 6.73M | 6.22M | 4.99M | 6.67M | 5.50M | 4.39M | 4.88M | 5.50M | 7.61M | 3.77M | 7.81M | 9.77M | 8.51M | 17.42M | 21.84M | 1.99M | 5.89M | 5.13M | 4.70M | 1.47M | 1.67M | 1.00M | 3.60M | 1.90M | 2.60M |
Gross Profit Ratio | 7.72% | 8.01% | 11.65% | 14.92% | 12.75% | 12.45% | 11.41% | 14.20% | 13.04% | 11.72% | 14.50% | 16.36% | 20.78% | 15.00% | 21.11% | 24.83% | 17.05% | 28.96% | 37.77% | 6.08% | 23.30% | 23.07% | 19.98% | 9.63% | 9.27% | 8.13% | 22.50% | 17.12% | 24.53% |
Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.28M | 0.00 | 3.26M | 0.00 | 0.00 | 4.11M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 17.00K | 0.00 | 133.00K | 0.00 | 0.00 | 278.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 3.63M | 3.94M | 3.81M | 3.70M | 3.47M | 3.52M | 3.29M | 3.48M | 3.39M | 3.46M | 3.53M | 4.39M | 8.11M | 3.45M | 11.36M | 14.23M | 24.28M | 19.38M | 16.74M | 13.10M | 5.30M | 3.83M | 3.91M | 3.76M | 3.28M | 3.30M | 3.20M | 2.50M | 2.00M |
Other Expenses | 0.00 | 40.00K | -93.00K | 57.00K | -274.00K | -18.00K | 101.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.20M | 0.00 | 0.00 | 0.00 | 378.64K | 400.00K | 400.00K | 300.00K | 300.00K |
Operating Expenses | 3.63M | 3.94M | 3.81M | 3.70M | 3.47M | 3.52M | 3.29M | 3.48M | 3.39M | 3.46M | 3.53M | 4.39M | 8.11M | 3.45M | 11.36M | 14.23M | 24.28M | 19.38M | 16.74M | 13.10M | 11.50M | 3.83M | 3.91M | 3.76M | 3.66M | 3.70M | 3.60M | 2.80M | 2.30M |
Cost & Expenses | 50.07M | 50.55M | 53.50M | 57.78M | 49.51M | 47.27M | 42.02M | 43.77M | 40.10M | 36.56M | 32.33M | 32.51M | 37.11M | 24.81M | 40.57M | 43.82M | 65.71M | 62.12M | 52.72M | 43.85M | 30.89M | 20.94M | 22.75M | 17.58M | 19.96M | 15.00M | 16.00M | 12.00M | 10.30M |
Interest Income | 0.00 | 13.00K | 128.00K | 256.00K | 397.00K | 630.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00K | 3.00K | 20.00K | 38.00K | 59.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Expense | 0.00 | 40.00K | 107.00K | 256.00K | 397.00K | 630.00K | 926.00K | 778.00K | 953.00K | 979.00K | 964.00K | 979.00K | 1.11M | 1.53M | 2.47M | 2.23M | 1.96M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Depreciation & Amortization | 1.22M | 1.15M | 834.00K | 826.00K | 772.00K | 774.00K | 348.00K | 393.00K | 351.00K | 405.00K | 390.00K | 425.00K | 500.00K | 361.00K | 454.00K | 517.00K | 1.62M | 1.43M | 1.17M | 1.59M | 952.53K | 455.62K | 361.33K | 353.88K | 378.64K | 400.00K | 400.00K | 300.00K | 300.00K |
EBITDA | 1.47M | 1.27M | 3.56M | 8.33M | 4.26M | 3.45M | 2.28M | 3.58M | 2.87M | 1.34M | 1.74M | 1.51M | -1.09M | 173.00K | -3.08M | -5.60M | -14.58M | -536.00K | 6.27M | -9.53M | -4.21M | 1.75M | 1.16M | -1.93M | -1.61M | -2.30M | 400.00K | -600.00K | 600.00K |
EBITDA Ratio | 2.93% | 2.57% | 4.98% | 10.49% | 5.98% | 6.92% | 4.90% | 7.34% | 5.84% | 3.57% | 5.17% | 4.58% | -0.01% | 2.73% | -8.31% | -9.90% | -29.19% | -1.05% | 10.73% | -37.08% | 4.61% | 6.35% | -1.48% | -14.35% | -43.45% | -17.89% | 2.50% | -6.31% | 5.66% |
Operating Income | 251.00K | 120.00K | 1.97M | 5.78M | 2.38M | 2.70M | 1.69M | 3.19M | 2.11M | 933.00K | 1.35M | 1.12M | -506.00K | 321.00K | -3.55M | -4.45M | -15.77M | -1.96M | 5.10M | -11.11M | -5.61M | 1.30M | 798.05K | -2.29M | -1.99M | -2.70M | 0.00 | -900.00K | 300.00K |
Operating Income Ratio | 0.50% | 0.24% | 3.50% | 9.10% | 4.52% | 5.41% | 3.88% | 6.79% | 5.01% | 2.49% | 4.01% | 3.32% | -1.38% | 1.28% | -9.59% | -11.31% | -31.57% | -3.26% | 8.83% | -33.95% | -22.19% | 5.83% | 3.39% | -14.95% | -11.07% | -21.95% | 0.00% | -8.11% | 2.83% |
Total Other Income/Expenses | 17.00K | -20.00K | -148.00K | 1.46M | -171.00K | -662.00K | -689.00K | -1.33M | -925.00K | -64.00K | -1.13M | -1.01M | -2.20M | -1.49M | -1.94M | -3.90M | -1.47M | -639.00K | -221.62K | 2.50M | 356.89K | 363.39K | 1.49M | 189.33K | 6.05M | -100.00K | 0.00 | 0.00 | 100.00K |
Income Before Tax | 268.00K | 100.00K | 2.60M | 7.25M | 3.09M | 2.04M | 1.01M | 1.86M | 1.19M | 869.00K | 220.00K | 110.00K | -2.70M | -1.17M | -5.50M | -8.35M | -17.23M | -2.60M | -4.88M | -8.61M | -5.25M | 1.66M | 2.28M | -2.10M | 4.06M | -2.80M | 0.00 | -900.00K | 400.00K |
Income Before Tax Ratio | 0.53% | 0.20% | 4.62% | 11.40% | 5.85% | 4.09% | 2.30% | 3.95% | 2.82% | 2.32% | 0.65% | 0.33% | -7.38% | -4.64% | -14.84% | -21.21% | -34.51% | -4.32% | -8.44% | -26.29% | -20.77% | 7.46% | 9.70% | -13.71% | 22.57% | -22.76% | 0.00% | -8.11% | 3.77% |
Income Tax Expense | 156.00K | 134.00K | -1.24M | -766.00K | -1.02M | 354.00K | 326.00K | -490.00K | 231.00K | 134.00K | 89.00K | 17.00K | 11.00K | 25.00K | 40.00K | 4.78M | 934.00K | -518.00K | -3.36M | -27.33K | 87.69K | 765.57K | 891.43K | -647.47K | 914.06K | -200.00K | 100.00K | -200.00K | 100.00K |
Net Income | 112.00K | -34.00K | 3.84M | 8.01M | 4.11M | 1.69M | 679.00K | 2.35M | 958.00K | 735.00K | 131.00K | 93.00K | -2.71M | -2.28M | -5.54M | -18.18M | -18.17M | -2.04M | 8.43M | -8.58M | -5.34M | 894.12K | 1.39M | -1.45M | 3.14M | -2.60M | -100.00K | -700.00K | 300.00K |
Net Income Ratio | 0.22% | -0.07% | 6.82% | 12.61% | 7.78% | 3.38% | 1.55% | 5.00% | 2.27% | 1.96% | 0.39% | 0.28% | -7.41% | -9.08% | -14.95% | -46.17% | -36.38% | -3.40% | 14.58% | -26.21% | -21.12% | 4.02% | 5.92% | -9.48% | 17.49% | -21.14% | -0.63% | -6.31% | 2.83% |
EPS | 0.00 | 0.00 | 0.13 | 0.27 | 0.14 | 0.06 | 0.02 | 0.11 | 0.05 | 0.03 | 0.01 | 0.00 | -0.13 | -0.11 | -0.27 | -0.93 | -1.26 | -0.15 | 0.43 | -0.68 | -0.48 | 0.12 | 0.22 | -0.24 | 0.61 | -0.50 | -0.02 | -0.17 | 0.07 |
EPS Diluted | 0.00 | 0.00 | 0.12 | 0.25 | 0.13 | 0.06 | 0.02 | 0.10 | 0.05 | 0.02 | 0.01 | 0.00 | -0.13 | -0.11 | -0.27 | -0.93 | -1.26 | -0.15 | 0.34 | -0.68 | -0.48 | 0.09 | 0.20 | -0.24 | 0.60 | -0.19 | -0.02 | -0.17 | 0.07 |
Weighted Avg Shares Out | 30.07M | 29.95M | 29.84M | 29.70M | 29.57M | 28.93M | 30.32M | 21.12M | 21.11M | 21.11M | 21.08M | 21.08M | 21.01M | 20.78M | 20.47M | 19.61M | 14.38M | 13.59M | 12.83M | 12.61M | 11.11M | 7.77M | 6.23M | 5.96M | 5.17M | 5.18M | 4.73M | 4.01M | 4.01M |
Weighted Avg Shares Out (Dil) | 30.87M | 29.95M | 32.32M | 32.11M | 31.16M | 29.59M | 30.32M | 30.17M | 21.19M | 29.39M | 21.19M | 21.24M | 21.01M | 20.78M | 20.47M | 19.61M | 14.38M | 13.59M | 16.23M | 12.61M | 11.11M | 10.42M | 7.11M | 5.96M | 5.26M | 13.58M | 4.73M | 4.01M | 4.01M |
Integrated BioPharma Reports Results for its Quarter Ended September 30, 2024
Integrated BioPharma Reports Results for Its Quarter and Fiscal Year Ended June 30, 2024
Integrated BioPharma Reports Results for its Quarter Ended March 31, 2024
Integrated BioPharma Reports Results for its Quarter Ended December 31, 2023
Integrated BioPharma Reports Results for its Quarter Ended September 30, 2023
Integrated BioPharma Reports Results for its Quarter and Fiscal Year Ended June 30, 2023
OTC Markets Group Welcomes Integrated BioPharma, Inc. to OTCQX
Integrated BioPharma: Strong Growth For Less Than A 5 P/E
Source: https://incomestatements.info
Category: Stock Reports